In individuals with obesity but without type 2 diabetes, subcutaneous Semaglutide has demonstrated effectiveness in weight loss, achieving an 11.85% reduction from baseline compared to a placebo. These findings endorse the utilization of semaglutide as a viable option for managing weight in cases of obesity.
Semaglutide injection belongs to a class of medications known as incretin mimetics. Its mechanism involves assisting the pancreas in releasing an appropriate amount of insulin in response to elevated blood sugar levels. Insulin facilitates the transfer of sugar from the bloodstream into various body tissues, where it is utilized for energy.
Semaglutide has demonstrated notable effectiveness in promoting weight loss in various clinical trials. For instance, a phase 3 trial conducted in 2021 showed that individuals with a body mass index (BMI) of 30 or above experienced an average weight reduction of 14.9% after 68 weeks of treatment with weekly injections of 2.4 milligrams of Semaglutide, compared to 2.4% in the placebo group. Semaglutide mimics the action of glucagon-like peptide-1 (GLP-1), leading to increased insulin secretion, reduced glucagon secretion, delayed gastric emptying, and enhanced feelings of fullness. These effects collectively contribute to decreased appetite, reduced food intake, and ultimately, weight loss. Moreover, Semaglutide may also improve metabolic health markers, such as blood sugar levels and cholesterol levels. Overall, Semaglutide represents a valuable option for individuals seeking effective weight management solutions.
Typically, individuals with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher accompanied by at least one weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol, may be eligible for Semaglutide treatment.
